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Abstract 
Previous epidemiological studies have suggested that the LpA-I subfraction of HDL is more protective than the LpA-I:A-II subfraction 
against the development of cardiovascular disease. A possible basis for a specific anti-atherogenic function of LpA-I emerged from 
studies of cholesterol efflux from cultured mouse adipocytes. LpA-I efficiently removed excess cholesterol from the mouse adipocytes, 
while LpA-I:A-II was ineffective. On the other hand, LpA-I:A-II was able to stimulate cholesterol efflux from a number of other cell 
types including rodent macrophages. Because of previously reported differences in HDL stimulation of cholesterol clearance from 
macrophages of different origins, we determined whether LpA-I:A-II could induce cholesterol efflux from cultured human monocyte- 
macrophages. Our findings showed that LpA-I:A-II and HDL, effectively stimulated cholesterol efflux from human monocyte-macro- 
phages enriched with cholesterol by incubation with AcLDL. LpA-I:A-II also decreased by one-half the amount of cholesterol 
accumulated when macrophages were incubated with AcLDL and LpA-I:A-II together. Thus, it would appear that the differential 
anti-atherogenic effects of LpA-I:A-II and LpA-I do not derive from their effects on macrophage cholesterol efflux. Possibly these HDL 
subfractions differentially affect other biologic processes that modulate the development of cardiovascular disease. 
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1. Introduction 
Because high density lipoprotein (HDL) levels are in- 
versely correlated with the risk of atherosclerotic heart 
disease [1,2], HDL is termed an anti-atherogenic lipopro- 
tein. HDL is comprised of two major subspecies that vary 
in their apolipoprotein content [3]. One type contains 
apoA-I but no apoA-II (LpA-I), and the other contains 
both apoA-I and apoA-II (LpA-I:A-II) [4,5]. As a result of 
this apoprotein difference, these two types of HDL may 
have different metabolic functions and clinical signifi- 
cance. 
Studies of the LpA-I and LpA-I:A-II concentrations in 
plasma samples of normal and coronary artery disease 
patients [6-81 support this possibility. These studies found 
that LpA-I but not LpA-I:A-II were decreased in nor- 
molipemic patients with angiographically documented 
coronary artery disease, when compared with a group of 
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patients with normal coronary arteries, and a group of 
asymptomatic subjects 161. Furthermore, it was observed 
that the level of LpA-I (but not LpA-I:A-II) in children 
whose parents suffer premature coronary artery disease is 
lower than the level in children with no familial history of 
coronary artery disease [7]. Luc et al. [8] also found that 
LpA-I was significantly elevated and LpA-I:A-II was re- 
duced in octagenerians as compared to levels in younger 
control subjects. LpA-I compared to LpA-I:A-II shows 
slightly more significant inverse correlation with myocar- 
dial infarction in another epidemiological ‘study [9]. To- 
gether, these studies suggest that LpA-I may represent an 
anti-atherogenic fraction of HDL. 
Accumulation of cholesterol by cells is a prominent 
characteristic of atherosclerotic lesions. As a result, there 
is a great deal of interest in the mechanism by which HDL 
removes cholesterol from cells. A possible basis for a 
specific anti-atherogenic function of LpA-I emerged from 
studies of cholesterol efflux from cultured mouse 
adipocytes [lo]. LpA-I efficiently removed excess choles- 
terol from OB 1771 mouse adipocytes, while LpA-I:A-II 
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was ineffective. However, other studies of cell types asso- 
ciated with the blood vessel wall such as endothelial cells, 
smooth muscle cells, and macrophages showed that LpA- 
I:A-II efficiently induced cholesterol efflux from these 
cells [ll-141. The macrophage is an important cell type 
found in atherosclerotic lesions. Macrophages accumulate, 
esterify, and store cholesterol in lipid droplets transforming 
the macrophages into so called foam cells. The previous 
studies of the positive effects of LpA-I:A-II on cholesterol 
efflux from macrophages were studies of mouse and rat 
peritoneal macrophages and macrophage cell lines [12,14]. 
The effect of LpA-I:A-II on cholesterol efflux from human 
monocyte-derived macrophages has not been reported. Be- 
cause of previously reported differences in HDL stimula- 
tion of cholesterol clearance from macrophages of differ- 
ent origins [15], we determined whether LpA-I:A-II could 
induce cholesterol efflux from cultured human monocyte- 
derived macrophages. 
2. Materials and methods 
2.1. Culture of monocyte-macrophages 
We prepared human monocytes from acid citrate/dex- 
trose-treated plasma (2.5 g of dextrose, 2.2 g of sodium 
citrate, and 0.73 g of citric acid per 100 ml of plasma) that 
was enriched with mononuclear cells by the process of 
monocytopheresis (model CS-3000, Fenwall). We obtained 
about 100 ml of this mononuclear cell-enriched plasma 
fraction, which also contained platelets and red blood cells. 
Mononuclear cells were further purified from this fraction 
and cultured as previously described [16]. 
10 * lo6 mononuclear cells were seeded into individual 
35mm diameter wells (cat. #606C, Plastek-C, 6-well 
cluster dishes, Tekmat) and incubated for 1 h at 37°C to 
allow monocytes to attach. Each well was then rinsed 
twice with 2 ml of RPMI-1640 to remove unattached cells. 
Monocyte cultures were incubated in 3 ml of RPMI- 
1640 containing 10% AB-human serum (heat-inactivated) 
to allow differentiation into macrophages. The medium 
was replaced with fresh medium after the first and second 
weeks of culture. All cell cultures and incubations were 
performed in a humidified 37°C incubator maintained with 
a 5% CO,/95% air atmosphere. 
2.2. Preparation of acetylated low density lipoprotein 
Low density lipoprotein (LDL) was isolated from nor- 
mal human plasma containing 0.01% disodium ethylene- 
diaminetetraacetic acid (EDTA) and 4% sodium citrate by 
sequential isopycnic ultracentrifugation [ 171 at densities 
1.019 g/ml and 1.063 g/ml. The density of the plasma 
was adjusted with solid KBr. Isolated LDL was washed by 
centrifugation at density 1.063 g/ml to ensure removal of 
HDL and proteins of higher density. The washed LDL was 
dialyzed against 0.15 M NaCl with 0.01% EDTA (pH 7.4) 
to remove the KBr, then made sterile by filtration through 
a 0.22 pm (pore-size) Millex GV filter (Millipore). The 
purity of the LDL was verified by agarose electrophoresis. 
Acetylated LDL (AcLDL) was prepared as described by 
Basu et al. [18]. 
2.3. Preparation of LpA-I:A-II and HDL, 
Blood was collected from healthy normolipidemic fe- 
male volunteers (who had fasted overnight) into tubes 
containing EDTA at a final concentration of 0.15%. The 
blood samples were immediately cooled on ice and all 
following steps were performed at 4°C. Plasma was pre- 
pared by centrifugation of blood for 20 minutes at 2000 X 
g. 
Human HDL of density 1.125-1.20 g/ml (HDL,), was 
isolated by density gradient ultracentrifugation from 
plasma. LpA-I:A-II was isolated from plasma by a previ- 
ously established immunoaffinity chromatography proce- 
dure [19]. Immunosorbents with rabbit polyclonal antibod- 
ies to apoE, and a mixture of monoclonal antibodies 
(GO3-G05-Gll) to apoA-II were prepared by coupling 
antibodies to CNBr-Sepharose 4B (Pharmacia). Im- 
munosorbents were equilibrated with 0.01 M phosphate- 
buffered saline (pH 7.4) containing 1 mM EDTA and 0.1% 
sodium azide. Plasma aliquots (6 ml) were absorbed with 
the anti-apoA-II immunosorbent to purify apoA-II-contain- 
ing lipoproteins (LpA-I:A-II) away from LpA-I without 
A-II. Lipoproteins bound to the immunosorbent were eluted 
with 3 M sodium thiocyanate and immediately desalted by 
passing through Sephadex G-25 (Pharmacia). Next, the 
HDL, and LpA-I:A-II lipoprotein fractions were applied 
to an anti-apoE immunosorbent to remove apoE-containing 
lipoproteins. 
All isolated lipoprotein particles were concentrated in a 
Micro-Prodicon device (Spectrum). The lipoprotein frac- 
tions were sterilized by filtration though a 0.22 pm (pore- 
size) Millipore filter and stored at 4°C. 
2.4. Analysis of lipoprotein fractions 
The protein content of lipoproteins was measured ac- 
cording to the method of Lowry [20]. Cholesterol content 
of lipoproteins was determined by the enzymatic-fluoro- 
metric method described by Gamble et al. [21]. Total 
phospholipid phosphorus was determined spectrophotomet- 
rically with the Fiske-SubbaRow method [22] as modified 
by Bartlett [23]. ApoE concentration was determined by 
radioimmunoassay [24]. 
Protein composition of the HDL lipoprotein particles 
was analyzed by sodium dodecyl sulfate polyacrylamide 
gel electrophoresis with a 4-20% gradient [25]. Lipopro- 
tein particle sizes were determined with nondenaturing 
polyacrylamide gel electrophoresis using 4-30% precast 
gradient gels (Pharmacia) as described [26,27]. Protein and 
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lipoprotein fractions were visualized after electrophoresis 
by staining with a solution of 0.03% Coomassie blue 
dissolved in methanol/acetic acid/water (25:10:45, v/v> 
and destained in the same solvent. Gels were scanned with 
a laser densitometer (Pharmacia). 
2.5. Incubation of monocyte-macrophages with lipopro- 
teins 
We enriched macrophages with cholesterol by incuba- 
tion with AcLDL (100 pg protein/ml) for 2 days in 
serum-free, RPMI-1640 medium with added penicillin- 
streptomycin (cat. #600-5140 AG, 10000 units/ml of 
penicillin G sodium and 10000 pg/ml of streptomycin 
sulfate in 0.85% saline, Life Technologies). At the end of 
the 2 days, the macrophages were rinsed twice with 3 ml 
RPMI-1640 medium and incubated for the desired amount 
of time in serum-free, RPMI-1640 medium alone or sup- 
plemented with LpA-I:A-II or HDL,. All lipoproteins 
were exhaustively dialyzed with RPMI-1640 medium be- 
fore being added to cultures at a concentration of 100 pg 
protein/ml. 
2.6. Determination of cholesterol and protein content of 
macrophages 
Macrophages were harvested after rinsing cultures three 
times with 3 ml of Ca’+- and Mg’+-containing Dulbecco’s 
phosphate-buffered saline (DPBS) and 0.35% bovine serum 
albumin and then three times with DPBS alone. We then 
scraped the cells (cat. #3010, Costar) into 2 ml of double- 
distilled water and kept them frozen at - 20°C until chemi- 
cal analysis was carried out. 
For analysis, cell samples were thawed and sonicated 
on ice for 30 s at a power setting of 25 W (sonifier #250, 
Branson). 100 ~1 of each sample was analyzed in dupli- 
cate for protein content with bovine serum albumin used as 
a standard [20]. For lipid analysis, 1.5 ml of each cell 
sample was extracted by the method of Folch et al. [28]. 
Unesterified and esterified cholesterol content of cell ex- 
tracts were determined in duplicate as described above for 
analysis of lipoprotein fractions [21]. 
2.7. Statistical analysis 
The variance was calculated as the standard error of the 
mean. Comparisons between conditions were determined 
with the two-tailed Student’s t-test. A P-value of 0.05 or 
less was considered a significant difference. 
3. Results 
3.1. Composition of HDL lipoprotein particles 
As expected, apoA-I, apoA-II and apoC were the major 
protein constituents of both LpA-I:A-II and HDL, (Fig. 1). 
ApoA-I - 
ApoA-II 7 
Apot? 
Fig. 1. SDS-PAGE of ApoA-I:A-II and HDL, particles. The lipoprotein 
samples (30 pg) were electrophoresed in 4-20% gels without reduction. 
The lanes from left to right are HDL,, LpA-LA-II, and standards whose 
molecular masses are (from top to bottom) 97.4, 69,46, 30, 21.5 and 14.3 
kDa. 
Neither LpA-I:A-II nor HDL, contained detectable apoE 
by radioimmunoassay. This confirmed the removal of 
apoE-containing lipoproteins by the immunoaffinity ab- 
sorption procedure. Table 1 shows the chemical composi- 
tion of the isolated lipoprotein particles. There was no 
significant difference in the lipid composition of LpA-I:A-II 
and HDL,. LpA-I:A-II and HDL, contained similar pro- 
portions of their cholesterol in esterified form (79 and 
78%). Also, the unesterified cholesterol to phospholipid 
molar ratios of LpA-I:A-II and HDL, were similar at 
0.20 f 0.03 and 0.23 f 0.01, respectively. 
3.2. Effect of LpA-I:A-II and HDL, on cholesterol eflux 
and cholesterol enrichment of macrophages 
Cholesterol efflux experiments were performed with 
four different cell preparations and three different prepara- 
tions of lipoprotein particles (Table 2). Prior to cholesterol 
enrichment with AcLDL, macrophages contained on aver- 
age (for the four preparations of macrophages) 78 + 3 
nmol/mg (cell protein) of unesterified cholesterol and 
Table 1 
Lipid composition of lipoproteins 
Constituent LpA-I:A-II (%) HDL, (%o) 
Total cholesterol 49 +4 51 *3 
Unesterified cholesterol 10 +2 12 +1 
Esterified cholesterol 39 +5 39 +5 
Phospholipid 51 +4 49 +3 
% EC/TC 79 +5 78 +1 
UC/PL 0.20 f 0.03 0.23 f 0.01 
Shown are the mean ( f S.E.1 lipid compositions of 3 different LpA-I:A-II 
and HDL, preparations isolated and analyzed as described in Materials 
and methods. There were no significant differences (P I 0.05) in their 
lipid compositions as determined with the Student’s t-test. TC, total 
cholesterol; EC, esterified cholesterol; UC, unesterified cholesterol; PL, 
phospholipid. 
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Effect of LoA-I:A-II on cholesterol efflux from macroohaces 
Incubation Conditions Experiment # (nmol total cholesterol/mg cell protein) 
1 2 3 4 
Day 0 77* 4 80 + 1 77+ 1 85 f 1 
AcLDL (2d) 128f 4 125 + 6 210+ 6 207 f 9 
AcLDL (2d); LpA-LA-II(2d) 76k 13 81 + 2 158 + 10 159 + 6 
AcLDL(2d); HDL, (2dl 81+ 2 92 + 2 159 + 7 143 * 2 
On day 0, 2-week-old human monocyte-macrophage cultures were rinsed and then received 2 ml RPMI-1640 medium containing 100 pg/ml AcLDL. 
Following incubation for 2 days, some cultures were rinsed and harvested as described in Materials and methods. Other cultures were rinsed twice with 3 
ml of RPMI-1640 medium and incubated with 2 ml RPMI-1640 medium containing either 100 pg/ml LpA-I:A-II or HDL, for an additional 2 days. 
These cultures were then harvested. Total cholesterol was analyzed and the means + S.E. of triplicate cultures are shown. Efflux with HDL, compared to 
LpA-I:A-II was significantly different in experiments 2 and 4. 
2 f 1 nmol/mg of esterified cholesterol. We have found 
variable accumulation of cholesterol in macrophages in- 
duced by different lots of AcLDL. Some lots of AcLDL 
produced low levels of cholesterol accumulation (e.g., 
experiments 1 and 2 in Table 2), while other lots produced 
significantly higher levels of cholesterol accumulation (e.g., 
experiments 3 and 4 in Table 2). 
As a result of loading macrophages with different lots 
of AcLDL in the experiments shown in Table 2, we were 
able to compare cholesterol efflux induced by LpA-I:A-II 
and HDL, from macrophages that had accumulated mini- 
mal amounts of cholesterol (about 50 nmol/mg in experi- 
ments 1 and 2) with efflux from macrophages that had 
accumulated more substantial amounts of cholesterol (> 
100 nmol/mg in experiments 3 and 4) during incubation 
with AcLDL. Efflux of cholesterol from macrophages with 
low and high levels of cholesterol enrichment was similar, 
ranging between 44 to 52 nmol/mg when macrophages 
were incubated with 100 pg/ml LpA-I:A-II for 2 days. 
HDL, induced efflw of 33 and 47 nmol/mg of choles- 
terol from the low cholesterol-enriched macrophages, and 
a somewhat higher amount of cholesterol, 51 and 64 
nmol/mg, from the high cholesterol-enriched 
macrophages. We examined the time course of cholesterol 
efflux from the cholesterol-enriched macrophages (Fig. 2). 
Macrophages incubated with LpA-I:A-II showed a pro- 
gressive decrease in total cholesterol content over a 3-day 
incubation period (Fig. 2b). HDL,-treated macrophages 
also decreased their cholesterol content during the first 2 
days of incubation in this experiment (Fig. 2c), and pro- 
gressively decreased their cholesterol content past 2 days 
in other experiments (not shown). Both lipoproteins selec- 
tively decreased the esterified cholesterol of the 
macrophages. By contrast, there was no decrease in the 
macrophage content of unesterified cholesterol that re- 
mained unchanged from the level reached during incuba- 
tion of macrophages with AcLDL. A small amount of 
cholesterol (19 nmol/mg) was lost from macrophages 
incubated without lipoproteins. 
In addition to stimulating cholesterol efflux from 
macrophages following their enrichment with cholesterol, 
LpA-LA-11 also limited macrophage cholesterol accumula- 
tion during incubation with AcLDL. LpA-I:A-II added at a 
level of 100 pg/ml significantly decreased the cholesterol 
accumulated by macrophages from 242 + 11 nmol/mg to 
202 f 8 nmol/mg during a 3-day incubation with 100 
pg/ml AcLDL (Fig. 3a and b). Addition of 200 pg/ml 
-A- 
t 
YE< 
loo -o-~~lJ~ 
50 
0 
b. LpA-l:A-II 
200 \ 
01 
0 1 2 3 
time (days1 
Fig. 2. Cholesterol efflux from monocyte-macrophages in the presence of 
LpA-I:A-II or HDL,. Two-week-old human monocyte-macrophage cul- 
tures were incubated with 2 ml of RPMI-1640 medium containing 100 
pg/ml AcLDL for 2 days. Then cultures were rinsed twice with 3 ml of 
RPMI-1640 medium and incubated for up to 3 days with 2 ml of (a) 
RPMI-1640 medium, (b) RPMI-1640 medium with 100 pg/ml LpA-I:A- 
II, or (c) RPMI-1640 medium with 100 pg/ml HDL,. The macrophage 
cultures were from experiment 3 shown in Table 2. Following incuba- 
tions, cultures were rinsed, harvested, and analyzed for their content of 
total cholesterol (TC, 01, esterified cholesterol (EC, A), unesterified 
cholesterol (UC, ??), and protein. Each point is the mean of triplicate 
cultures. The S.E. bars are not shown if they were smaller than the height 
of the symbol. Prior to cholesterol-enrichment with AcLDL, macrophages 
contained 77& 1 nmol/mg of TC, 76 *2 nmol/mg of UC, and 1 + 1 
nmol/mg of EC. 
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of LpA-I:A-II produced an even greater decrease in the 
level of cholesterol that accumulated to only 159 f 9 
nmol/mg (data not shown). HDL, added at a level of 100 
pg/ml decreased AcLDL-induced cholesterol accumula- 
tion to 200 f 11 nmol/mg (Fig. 3~). 
3.3. Effect of cholesterol efjlux on HDL particle size 
With nondenaturing gel electrophoresis, we analyzed 
the particle sizes of HDL, and LpA-I:A-II before incuba- 
tion and following incubation with and without 
macrophages (Fig. 4). Before incubations, the distribution 
of HDL, particles was relatively homogeneous with a 
modal diameter of 8.4 nm (size ranged between 7.5-11.2 
nm) (Fig. 4a). The distribution of LpA-I:A-II particles 
(also prior to incubation) suggested the presence of 3 
subpopulations with sizes that also ranged between 7.5- 
11.2 nm (Fig. 4b). There was a major subpopulation of 
LpA-I:A-II particles with a modal size of 8.7 nm. There 
were two minor LpA-I:A-II particle subpopulations one 
a. AcLDL 
250 
t 
b. AcLDL + LpA-l:A-Ii 
250 
c. AcLDL + HDL3 
time (days) 
Fig. 3. Effect of LpA-LA-II and HDL, on monocyte-macrophage choles- 
terol accumulation during incubation with AcLDL. 2-week-old human 
monocyte-macrophage cultures were incubated up to 3 days with 2 ml of 
RPM&1640 medium containing (a) 100 pg/ml AcLDL, (b) 109 pg/ml 
AcLDL plus 100 pg/ml LpA-I:A-II, or (c) 100 pg/ml AcLDL plus 100 
pg/ml HDL,. Following incubations, cultures were rinsed, harvested, 
and analyzed for their content of total cholesterol (TC, 01, esterified 
cholesterol (EC, A ), unesterified cholesterol (UC, ??), and protein. Each 
point is the mean of triplicate cultures. The S.E. bars are not shown if 
they were smaller than the height of the symbol. 
9.2 9.2 11.2 17.0 
stokes diameter (nm) 
Fig. 4. Electrophoretic analysis of size of LpA-I:A-II and HDL,. Mono- 
cyte-macrophages were enriched with cholesterol by incubation with 100 
pg/ml AcLDL for 2 days. Then, macrophages were incubated for 3 days 
in RPMI-1640 with 100 pg/ml of (a) HDL, or (b) LpA-I:A-II. HDL, 
and LpA-I:A-II before incubation (solid line) and after incubation with 
macrophages (dotted line) were subjected to nondenaturing gradient 
(4-30%) polyacrylamide gel electrophoresis. The gels were stained with 
Coomassie blue. Densitometric scans of the stained gels are shown. Scans 
for HDL, and LpA-I:A-II incubated without macrophages (not shown) 
were similar to those shown for these lipoproteins incubated with 
macrophages. 
smaller (at 8.0 nm) and one larger (at 10.1 nm) than the 
major distribution of LpA-I:A-II particles. 
Incubation of the HDL, and LpA-I:A-II particles 
slightly shifted the size distributions of both types of HDL 
towards larger particles (Fig. 4). The modal size of the 
incubated HDL, increased to 8.9 nm, while the modal 
diameter of the major subpopulation of incubated LpA- 
I:A-II increased to 9.1 nm. The smaller LpA-I:A-II sub- 
population increased to 8.2 nm and the larger LpA-I:A-II 
subpopulation was no longer apparent. The shift in size 
distribution occurred during incubation with or without 
macrophages. Thus, the shift in size was due to the 
incubation of the particles at 37°C rather than to any 
specific macrophage-mediated effect. 
4. Discussion 
Our results show that the LpA-I:A-II subfraction of 
HDL efficiently stimulates cholesterol efflux from human 
monocyte-derived macrophages. This is in contrast to the 
results obtained previously with OB 1771 mouse adipocytes 
for which LpA-I:A-II did not stimulate cholesterol efflux 
[6]. Thus, our results for human monocyte-macrophages 
are consistent with two previous reports that also showed 
LpA-I:A-II can stimulate cholesterol efflux from rat and 
mouse peritoneal macrophages [12,14]. In addition, LpA- 
I:A-II has been shown to stimulate cholesterol efflux from 
other cell types including human skin fibroblasts, rat hep- 
atoma cells, bovine aortic endothelial cells, and rabbit 
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aortic smooth muscle cells [11,13]. As in these previous 
studies of non-adipocyte cultured cells, LpA-I:A-II was as 
efficient as LpA-I in promoting cholesterol efflux from the 
human monocyte-macrophages in one preliminary experi- 
ment (unpublished data). 
A number of factors could explain the different results 
obtained with the adipose cells compared with the 
macrophage and other cell types. First, cholesterol accu- 
mulation in the mouse adipocytes is exclusively unesteri- 
fied as these cells do not esterify cholesterol they accumu- 
late [29]. The accumulation of cholesterol and its storage in 
a predominantly unesterified form also is a characteristic 
of cholesterol stored in human adipose tissue [30]. Thus, 
the pool of cholesterol available for efflux in the mouse 
adipocytes is very different than the pool of cholesterol 
that accumulates in macrophages during incubation with 
lipoproteins. The macrophage cholesterol is predominantly 
esterified cholesterol that is stored in lipid droplets [31]. A 
second difference between our study and the study with 
the mouse adipocytes was that we induced cholesterol 
enrichment by incubating macrophages with AcLDL. In 
the mouse adipocyte studies, cholesterol-enrichment was 
produced by incubating these cells with LDL. Most cul- 
tured cells show predominantly accumulation of cholesteryl 
ester when incubated with LDL [32]. However, we did not 
attempt to study efflux from human monocyte-macro- 
phages that were cholesterol-enriched with LDL, because 
only low levels of cholesterol-enrichment could be attained 
with this lipoprotein (unpublished observations). On the 
other hand, we were able to more substantially elevate 
cholesterol levels in human monocyte-macrophages with 
AcLDL. However, it is unlikely that the method of choles- 
terol enrichment of the macrophages and adipocytes re- 
sulted in the susceptibility of the macrophages to lose 
cholesterol in the presence of LpA-I:A-II. This is because 
efflux in other cell types with LpA-I:A-II has been demon- 
strated with a variety of methods of cellular cholesterol 
enrichment [11,13]. 
LpA-I:A-II not only could induce cholesterol efflux 
from macrophages that had been first enriched with choles- 
terol, and then incubated with LpA-I:A-II, but also limited 
cholesterol-accumulation when incubated together with 
AcLDL. This result is relevant to the situation that most 
likely exists in atherosclerotic lesions where cholesterol 
efflux must occur in the presence of extracellular deposits 
of lipoprotein and non-lipoprotein cholesterol [33,34]. 
Therefore, it is interesting that LpA-I:A-II and HDL, 
could limit cholesterol accumulation during as well as after 
exposure of macrophages to lipoproteins. This finding is 
similar to what was found previously by Innerarity et al. 
who showed HDL, limited cholesterol accumulation by 
mouse peritoneal macrophages when these cells were incu- 
bated with /3-VLDL and HDL, together 1351. In that 
study, the HDGmediated decrease in cholesterol accumu- 
lation was not due to decreased uptake of cholesterol, but 
rather, was due to efflux of cholesterol after it had been 
taken up by the cells. LpA-I:A-II and HDL, both de- 
creased the accumulation of cholesterol by about 40 
nmol/mg cell protein in macrophages incubated for 3 days 
with AcLDL the HDL together. This decrease in choles- 
terol content was somewhat less than the 48 to 64 nmol/mg 
reduction in cholesterol content that occurred when 
macrophages were incubated with 100 pg/ml of LpA- 
I:A-II or 100 pg/ml of HDL, for 3 days after 
cholesterol-enrichment. However, doubling the LpA-I:A-II 
concentration during incubation of macrophages with 
AcLDL, doubled the decrease in cholesterol accumulation. 
Thus, LpA-I:A-II could limit cholesterol accumulation by 
macrophages to the same extent whether LpA-I:A-II was 
added during or following cholesterol-enrichment. 
Although there was a small increase in the sizes of 
HDL, and the main component of LpA-I:A-II, the increase 
in sizes occurred during incubation of the lipoproteins in 
the presence and absence of macrophages. Therefore, the 
increase in size of the incubated lipoproteins did not result 
from their acquiring apoE and cholesterol during choles- 
terol efflux as was demonstrated in other cell culture efflux 
systems [36]. The increase in size of the HDL in the 
present experiments may have reflected remodeling of 
HDL particles as previously described [37]. 
The fact that LpA-I:A-II does not induce cholesterol 
efflux from mouse adipocytes suggests that the function of 
HDL with respect to adipose cells may be different than its 
function with respect to other cells such as macrophages. 
This possibility is supported by the finding that not only 
does LpA-I:A-II fail to stimulate cholesterol efflux from 
mouse adipocytes, it also inhibits that cholesterol efflux 
stimulated by the LpA-I subfraction of HDL [38]. Also, 
Fong and Angel [39] have shown that unfractionated HDL 
can function to deliver cholesterol to human adipocytes. 
This is further evidence that HDL function with respect to 
adipocytes is more complex than with other cells. It is 
possible that under some conditions HDL delivers choles- 
terol to adipocytes and at other times may remove choles- 
terol from these cells depending on varying metabolic 
conditions. A dual function for HDL may reflect the fact 
that adipose tissue is a major storage site for cholesterol as 
it is for triglyceride [40]. On the other hand, HDL may 
function most of the time to remove cholesterol accumu- 
lated by macrophages as these cells remove lipoproteins 
and dead cells from tissues. 
Recent studies in transgenic mice with high levels of 
LpA-I or LpA-I:A-II HDL subclasses have confirmed that 
LpA-I is more protective against the development of 
atherosclerosis than is LpA-I:A-II [41,42]. It remains pos- 
sible that the greater protective effect of LpA-I over 
LpA-I:A-II comes from effects of these HDL particles 
unrelated to their stimulation of cholesterol efflux. Rather, 
protection could be related to different effects of these 
lipoproteins as antioxidants [43], reactivity with plasma 
proteins that influence HDL metabolism [19&l-47], and 
cellular signaling pathways [48]. Further research is re- 
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quired to clarify the basis for the different protective 
effects of LpA-I and LpA-I:A-II on the development of 
cardiovascular disease. 
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